Commercializing Understudied Proteins from the Illuminating the Druggable Genome Project (IDG) (R43/R44 Clinical Trial Not Allowed)

0
25
Federal grants application on Grants.Gov

Funding Opportunity ID:309853
Opportunity Number:PA-19-034
Opportunity Title:Commercializing Understudied Proteins from the Illuminating the Druggable Genome Project (IDG) (R43/R44 Clinical Trial Not Allowed)
Opportunity Category:Discretionary
Opportunity Category Explanation:
Funding Instrument Type:Grant
Category of Funding Activity:Education
Health
Category Explanation:
CFDA Number(s):93.121
93.242
93.350
93.393
93.394
93.395
93.396
93.399
93.879
Eligible Applicants:Small businesses
Additional Information on Eligibility:Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
Agency Code:HHS-NIH11
Agency Name:Department of Health and Human Services
National Institutes of Health
Posted Date:Oct 24, 2018
Close Date:Sep 05, 2021
Last Updated Date:Oct 24, 2018
Award Ceiling:$0
Award Floor:$0
Estimated Total Program Funding:
Expected Number of Awards:
Description:The goal of this funding opportunity announcement (FOA) is to solicit applications from small business concerns (SBCs) to initiate early research ultimately leading to the commercialization of understudied proteins identified in the "Illuminating the Druggable Genome" project (IDG; https://commonfund.nih.gov/idg/index ). The purpose of the IDG is to reveal the function of selected understudied proteins in the druggable genome. Organized as a consortium, the project consists of multiple Data and Resource Generation Centers (DRGCs), a Knowledge Management Center (KMC), a Resource Dissemination and Outreach Center (RDOC) and projects developing Cutting Edge Informatics Tools (CEITs). Small businesses are expected to complement the IDG Centers by proposing projects to commercially validate reagents, data or experimental approaches. Projects could range from early proof-of-concept demonstration and assay development/validation to the initiation of preclinical drug discovery projects.
Version:1





Visit the Official Webpage For More Details on Commercializing Understudied Proteins from the Illuminating the Druggable Genome Project (IDG) (R43/R44 Clinical Trial Not Allowed)